Suzhou, China, February 27, 2026 — Keythera (Suzhou) Biopharmaceuticals Co., Ltd. (“Keythera”) today announced that the abstract of its exploratory Phase 2a clinical study of KF-0210, an orally administered EP4 receptor antagonist for the treatment of knee osteoarthritis, conducted in collaboration with The First Hospital of Jilin University, has been accepted as a Podium Presentation at the 2026 OARSI World Congress on Osteoarthritis (OARSI 2026). The presentation will be featured in the session titled “Highest Rated Late Breaking Abstracts.”

According to the official notification, the study will be presented orally on April 25, 2026, 5:25 PM (local time) at the OARSI 2026 World Congress in West Palm Beach, Florida, USA. The presentation is titled:

"Clinical and Biological Rationale for KF-0210, an Oral EP4 Antagonist Demonstrating Rapid and Deep Symptom Relief in Knee Osteoarthritis: Results from an Exploratory Phase 2a Study".  Publication Number: 138

The OARSI Program Committee has also confirmed that all accepted abstracts will be published in a supplement issue of the official OARSI journal, Osteoarthritis and Cartilage, following the Congress.

The Phase 2a study is an exploratory clinical trial designed to evaluate the preliminary efficacy and safety of KF-0210 in patients with knee osteoarthritis. Study results demonstrated rapid onset of symptom improvement and clinically meaningful symptom relief trends, along with a favorable safety and tolerability profile in the study population.

The study was conducted in collaboration with The First Hospital of Jilin University, with contributions from Principal Investigators Dr. Xin Qi, Dr. Yanhua Ding, and their clinical teams.

Dr. Yongqi Deng, Chief Executive Officer of Keythera, stated:

"We are honored that our study has been accepted as a Podium Presentation in the 'Highest Rated Late Breaking Abstracts’ session at OARSI 2026. We appreciate the collaboration and dedication of our clinical partners at The First Hospital of Jilin University. We also want to thank all the patients and their families for participating in the clinical trial and look forward to sharing our findings with the global osteoarthritis research community.

      About KF-0210

KF-0210 is a highly selective, orally administered EP4 receptor antagonist designed to block the PGE₂–EP4 signaling pathway, thereby exerting anti-inflammatory and analgesic effects without inhibiting the synthesis of PGE₂ or PGI₂. Preclinical studies have demonstrated anti-inflammatory and analgesic activity, as well as potential cartilage-protective properties.

       About OARSI

The Osteoarthritis Research Society International (OARSI) is an international organization dedicated to advancing research and education in osteoarthritis. The OARSI World Congress serves as a global forum for presenting cutting-edge scientific and clinical advances in the field.

       About Keythera

Keythera is a clinical-stage biopharmaceutical company focused on the development of innovative small-molecule therapies in oncology, autoimmune diseases, and other areas of significant unmet medical need.

Back to List